NCT04968574: An ongoing trial by Endeavor Biomedicines, Inc.
This trial is completed, but has been granted a delay in reporting its results.
It must report results 11 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04968574 |
|---|---|
| Title | A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 26, 2021 |
| Completion date | Nov. 30, 2023 |
| Required reporting date | Nov. 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |